Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10460)	2/17/2004 11:07:00 AM
From: rkrw	Read Replies (1) \| Respond to of 52153

What sepr doesn't tell us can drive the price as well. crxa anyone? :-) I do agree the outcome can certainly be categorized. My outlook: Approvable pending label: 50%, stock jumps to >$30 Approvable new animal studies needed: 20%, $20 Approvable, new human studies needed 20%, Stock drops to high teens-$20 Not approvable: 10%, mid high teens Long term label: 1% I'm not going to worry about review cycle. sepr keeps changing their mind on what it means, what they expect and how its communicated. What matters to me is that they get a clean approval, no new trials needed and a 2004 launch. Anything less than that is a negative outcome. Price est are within first week post decision.